Demystifying Medicine 2017
Tuesdays: January 10 through May 23
4:00pm - 6:00pm
Building 50 Conference Room
(unless otherwise noted)
Final Examination - Deadline is May 25, 2017 at 5:00pm ET
January 10 - Mitochondria, Aging, and Chronic Disease
- Richard Hodes, MD (NIA) - Richard J. Hodes, M.D., directs the research program of the National Institute on Aging (NIA) at the National Institutes of Health. A leading immunologist, Dr. Hodes was named Director of the NIA in 1993, to oversee studies of the biological, clinical, behavioral and social aspects of aging.
Under Dr. Hodes' stewardship, the NIA budget has grown to nearly $1.6 billion, reflecting increased public interest in aging as America and the world grow older. Dr. Hodes has devoted his tenure to the development of a strong, diverse, and balanced research program, focusing on the genetics and biology of aging, basic and clinical studies aimed at reducing disease and disability, including Alzheimer's disease, related dementias, and age-related cognitive change, and investigation of the behavioral and social aspects of aging. Ultimately, these efforts have one goal - improving the health and quality of life for older people and their families.
The NIA has led new and innovative ways to conduct research, share data and translate findings into practical interventions and public information. In biology, studies examine genetic and other factors influencing aging, how they affect longevity and how they intersect with the development of age related diseases. Research in geriatrics is uncovering new ways to combat frailty and other age-related conditions. Behavioral and social research is deepening understanding of the individual behaviors and societal decisions that affect well-being.
Dr. Hodes also directs the Federal research effort to find effective ways to treat or prevent Alzheimer's disease and related dementias. The NIA is the NIH lead in research on these dementias, and cutting edge research conducted and supported by the Institute has helped revolutionize the way we think about these diseases. Studies in genetics, basic mechanisms, imaging and biomarkers have spurred the development of potential therapies aimed at a variety of targets and the testing of interventions at the earliest signs of disease. Dr. Hodes represents NIH on the HHS Secretary's Federal Advisory Council on Alzheimer's Disease Research, Care, and Services and coordinates the NIH research efforts under the National Plan to Address Alzheimer's Disease.
Dr. Hodes is a graduate of Yale University and received his M.D. from Harvard Medical School. He completed training in Internal Medicine at Massachusetts General Hospital and in Oncology at the National Cancer Institute. Dr. Hodes is a Diplomate of the American Board of Internal Medicine, a member of The Dana Alliance for Brain Initiatives, a Fellow of the American Association for the Advancement of Science, and a member of the Institute of Medicine of the National Academy of Sciences. As an author of more than 250 research papers, he is an influential scientist in and contributor to the field of immunology.
- Toren Finkel, MD, PhD (NHLBI) - Biosketch - Toren Finkel, M.D., Ph.D., joined the National Heart, Lung, and Blood Institute (NHLBI) in 1992 as Investigator, Cardiology Branch. He was named Chief of the Cardiology Branch in the Institute's Division of Intramural Research in 2001. Dr. Finkel's primary research interests are in oxidant or free radical-mediated diseases, aging, and the cardiovascular clinical implications of stem cells.
Dr. Finkel received his M.D. from Harvard Medical School, Boston, MA in 1986. That same year, he received his Ph.D. in Biophysics from the Harvard University School of Arts and Sciences. He graduated summa cum laude in 1979 with a B.S. in Physics from the University of Maryland, College Park. Dr. Finkel pursued a Fellowship in Cardiology at the Johns Hopkins University Hospital from 1989-1992. He conducted his Internship and Residency in Internal Medicine at Massachusetts General Hospital from 1986-1987 and 1987-1989, respectively.
Dr. Finkel is the author or coauthor of over 80 publications. He has edited one book and is Editor-in-Chief of Drug Discovery Today-Disease Mechanisms. Dr. Finkel also is the Associate Editor of Circulation Research and is on the editorial boards of several peer-reviewed journals.
January 17 - Addiction and Habituation: Drugs and Food
- Nora Volkow, MD, PhD (NIDA) - Biosketch
- Kevin Hall, PhD (NIDDK) - Biosketch
January 24 - New Approach to Atherosclerosis from Studies of Chronic Granulomatous Disease
- John I. Gallin, MD (CC) - Biosketch
January 31 - Glycoproteins, Allergy, and Other Diseases
- John Hanover, PhD (NIDDK) - Biosketch
- Michelle Bond, PhD (NIDDK) - Biosketch
- Jonathan Lyons, MD (NIAID) - Biosketch
February 7 - CANCELED: Inflammation: Cytokine Storm
- Irini Sereti, MD (NIAID)
- Richard Childs, MD (NHLBI)
February 14 - Inflammation: One Gene at a Time
- Dan Kastner, MD, PhD (NHGRI) - Kastner Group Website -
Dr. Dan Kastner obtained his A.B. summa cum laude in philosophy from Princeton University and a Ph.D. and M.D. from Baylor College of Medicine. After completing an Internal Medicine residency and chief residency also at Baylor, Dr. Kastner moved to the NIH in 1985. He completed clinical Rheumatology training in the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and then rose through the NIAMS faculty ranks to become NIAMS Clinical Director from 2005 to 2010. From 2008 to 2011 he was also the first NIH Deputy Director for Intramural Clinical Research. Since late 2010 he has served as Scientific Director of the Division of Intramural Research of the National Human Genome Research Institute (NHGRI). Throughout his career at the NIH Dr. Kastner's research has focused on using genetic and genomic strategies to understand inherited disorders of inflammation, often stimulated by patients seen at the NIH Clinical Center. Dr. Kastner's laboratory identified the gene mutated in familial Mediterranean fever by positional cloning, discovered the genetic basis for a second recurrent fever syndrome they named TRAPS (TNF receptor-associated periodic syndrome), and made seminal genetic discoveries that establish other distinct illnesses as disorders of the IL-1 pathway, thus helping to define the role of IL-1 in human biology and establishing the conceptual basis for therapeutic trials with IL-1 inhibitors. More recently his laboratory has utilized genomic approaches in genetically complex disorders, such as Behçet's disease, and Dr. Kastner continues to maintain a very active clinical research program. His group also proposed the now widely accepted concept of autoinflammatory disease to denote disorders of innate immunity. Dr. Kastner has won a number of awards and honors, including election to the National Academy of Sciences in 2010 and to the Institute of Medicine of the National Academies in 2012.
February 21 - Inflammation and Pancreatic Cancer
- S. Perwez Hussain, PhD (NCI)
- Christine Alewine, MD, PhD (NCI)
February 28 - HIV: Frontiers and Vaccine Development
- John Coffin, PhD (NCI)
- Jeffrey Lifson, MD (NCI) - Biosketch, Brief Description
March 7 - Hepatocellular Cancer and Liver Transplantation
- T. Jake Liang, MD (NIDDK) - Biosketch
- Lynt B. Johnson, MD, MBA (Chair, Department of Surgery, MedStar Georgetown University Hospital)
March 14 - Genetic Disease Testing: Current Status and Future Prospects
- Robert Nussbaum, MD (Chief Medical Officer, Invitae Corporation) - Medical genetics pioneer from UCSF to join executive team to lead medical organization SAN FRANCISCO - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the appointment of Robert L. Nussbaum, M.D. as Chief Medical Officer; such appointment will become effective August 1, 2015. As a board-certified internist and medical geneticist, Dr. Nussbaum has dedicated his career to improving the care of adults and children with hereditary disorders.
Dr. Nussbaum was most recently chief of the Division of Genomic Medicine at UCSF Health and has played leadership roles in the Cancer Genetics and Prevention Program and in the Program in Cardiovascular Genetics. As a member of the UCSF Institute for Human Genetics for the past nine years, Dr. Nussbaum will bring to Invitae extensive expertise in using genetic information to better healthcare by improving outcomes, lowering costs and promoting education.
Dr. Nussbaum, a member of the Institute of Medicine and a fellow at the American Academy of Arts and Sciences, was co-discoverer of the first inherited form of Parkinson's disease. He has since worked to identify the genetic contributions to the disease as well as carrying out basic research into its pathogenesis. Prior to joining UCSF, Dr. Nussbaum was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute, one of the National Institutes of Health.
"For decades, we have been advancing our understanding of the human genome. We are now at that exciting point of time that many of us have worked towards all these years, when the field is starting to have a real impact both on medical care and on the health of individuals and the public," said Dr. Nussbaum. "I am joining Invitae because I believe its commitment to science and quality patient care will help make genetic information more affordable and accessible in a way that benefits patients, clinicians and the healthcare system. I am particularly excited about Invitaes commitment to empowering patients to participate in the genomics revolution by sharing their data in order to advance the quality of genetic testing and, more generally, improve medical care and disease prevention."
Dr. Nussbaum will serve as part of Invitae's executive team and lead its medical organization, overseeing medical genetics, clinical genetics, genetic counseling, clinical development and medical affairs. Dr. Nussbaum plans to continue his clinical activities at UCSF as a volunteer physician after joining the Invitae team.
"Bob is one of the pioneers in the field of genetics. We're humbled that he has agreed to join us and expect that he will play a leading role in helping us achieve our mission," said Randy Scott, chief executive officer of Invitae. "We believe that the best way to bring genetics to billions of patients around the world is to work with the medical community and payors to improve care and reduce the cost of healthcare. Bob's leadership will be invaluable as we pursue our mission."
Dr. Nussbaum graduated from Harvard Medical School in the Harvard-MIT joint program, and completed his residency in internal medicine at Barnes-Jewish Hospital and a fellowship in medical genetics at the Baylor College of Medicine.
- Leslie Biesecker, MD (NHGRI) - Research Group Website - Scientific Summary
March 21 - Fibrosis: Inflammation and Cirrhosis
- Thomas Anthony Wynn, PhD (NIAID)
- Theo Heller, MD (NIDDK)
March 28 - Obesity: Brown and Other Fat
- Aaron Cypess, MD, PhD, MMSc (NIDDK)
- Rebecca Brown, MD, MHSc (NIDDK)
April 4 - Sight-threatening Uveitis: a 2-way Street between Research and Clinic
- Mary Mattapallil, PhD (NEI) - Biosketch
- Sapna Gangaputra, MD, MPH (NEI) - Sapna Gangaputra, MD, MPH is currently a clinical fellow in the Laboratory of Immunology at the National Eye Institute (NEI) of National Institutes of Health (NIH). Dr. Gangaputra completed her ophthalmology residency at University of Wisconsin-Madison prior to her uveitis and ocular immunology fellowship at the NEI. She also obtained her Masters in Public Health at Johns Hopkins Bloomberg School of Public Health in 2005. Dr. Gangaputra has extensive experience in retinal imaging and has been a part of several multicenter clinical trials on diabetic retinopathy, age related macular degeneration and uveitis, funded by NIH as well as industry. She has worked as co-director of a highly prestigious ophthalmic imaging center. Dr. Gangaputra has authored over 40 peer- reviewed articles and is well recognized in the American Uveitis Society. She will be completing her fellowship in July 2017 and joining Vanderbilt Eye Institute as Assistant Professor of Ophthalmology, specializing in ocular inflammatory diseases.
April 11 - Alzheimer: What, When and How
- Mark Mattson, PhD (NIA)
- Dimitrios Kapogiannis, MD (NIA)
April 18 - Bioengineering: Bridging Brain, Computer, and Neurologic Disease
- Jonathan Wolpaw, MD (National Center for Adaptive Neurotechnologies) - Biosketch
April 25 - Addison's Disease meets Chromatin Biology
- Lynnette Nieman, MD (NICHD)
- Daniel Larson, PhD (NCI)
May 2 - POSTPONED UNTIL MAY 16: Current Infectious Disease Challenges
- Anthony S. Fauci, MD (NIAID)
May 9 - Schizophrenia: From Childhood to Genomes
- Judy Rapoport, MD (NIMH)
- Joshua Gordon, MD, PhD (NIMH)
May 16 - Current Infectious Disease Challenges
- David M. Morens, MD (NIAID) - Biosketch
This web page was last modified on 17 May 2017. For questions about the course, please contact firstname.lastname@example.org.